CD177 and neoplasm: Although FOLR1, like the vast majority of cell surface receptors, is not exclusively expressed on tumor cells, its expression profile in ovarian and lung cancer patients is considered conductive for FOLR1-targeting interventions such as mAbs, antibody-drug conjugates (ADCs), and small molecule drug conjugates, all of which were generally tolerated in clinical trials (31–33).